The anti-mesothelin monoclonal antibody amatuximab enhances the anti-tumor effect of gemcitabine against mesothelin-high expressing pancreatic cancer cells in a peritoneal metastasis mouse model

Pancreatic cancer often has a very poor prognosis, even after complete resection. The recurrence of hepatic and peritoneal metastases is an important prognostic factor; therefore, the development of improved adjuvant therapy is urgently required. Mesothelin is a cell surface glycoprotein whose expre...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oncotarget
Egile Nagusiak: Mizukami, Tatsuzo, Kamachi, Hirofumi, Fujii, Yuki, Matsuzawa, Fumihiko, Einama, Takahiro, Kawamata, Futoshi, Kobayashi, Nozomi, Hatanaka, Yutaka, Taketomi, Akinobu
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Impact Journals LLC 2018
Gaiak:
Research Paper
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6173461/
https://ncbi.nlm.nih.gov/pubmed/30333914
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.26117
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak